India's Parkinson's Surge: Why Young-Onset Cases are Rising

India's Parkinson's Surge: Why Young-Onset Cases are Rising

Read More
Full Text
last month

India faces a major public health crisis due to a projected surge in Parkinson's disease India cases. Experts at the 6th International Annual Symposium-2026 in Kerala delivered a stark warning. They now expect India to become the country with the second-highest number of Parkinson's patients globally within five years. Ultimately, this alarming projection highlights a critical and growing neurological challenge for the nation. Consequently, the King's Parkinson's Research Alliance India (PRAI) symposium brought together global experts to discuss emerging challenges and innovative care.



Rising Burden of Young-Onset Parkinson's Disease India


Parkinson's disease is traditionally an older population ailment. However, symposium experts noted increasing diagnoses among younger individuals in Southeast Asia, including India. Therefore, the issue of young-onset Parkinson's (YOPD) is a known regional concern. This trend creates unique social, economic, and healthcare challenges for working-age patients. Furthermore, India’s current prevalence rate is 15-43 per 100,000. Experts project cases will increase significantly by 2030.


A significant portion of Indian cases are early-onset. Specifically, about 40 to 45% occur between the ages of 22 and 49. The average onset age is roughly 51 years. Doctors link the disease surge to several environmental and lifestyle factors. These include increased industrialisation, worsening air pollution, and changing lifestyles. Additionally, specific factors in North India—such as male gender, genetic history, and head injuries—show an association with a higher prevalence. This progressive neurodegenerative disorder, the second most common in adults over 60, demands enhanced public health policies.



Prioritizing Affordable Treatment and Research


Speakers at the symposium strongly emphasised the need for early diagnosis. Moreover, they called for region-specific research and affordable treatment options tailored to the Indian population. The event also highlighted emerging therapies and technological innovations set to transform Parkinson's treatment. Vinod Mehta, a Movement Disorders specialist, stressed the importance of empowering patients and caregivers. He stated that plenty of treatment options and novel therapies are now available.


King's College Hospital London, in collaboration with PRAI, is currently developing new technologies, like a treatment patch. This innovation must be made affordable through local manufacturing. Currently, patients sometimes pay ₹1 lakh per month for advanced treatments. Conversely, local manufacturing could potentially drop the cost to ₹1,000 per month, benefiting millions. International collaboration and supportive public health policies can dramatically reduce treatment costs. Additionally, researchers noted that Indian populations present a unique genetic landscape, including the p.Leu444Pro mutation, which is linked to earlier onset. Ultimately, long-term strategies require training healthcare professionals, strengthening research infrastructure, and increasing public awareness.



Frequently Asked Questions


Q1: Why is India expected to see a Parkinson's disease surge?


India is projected to become the country with the second-highest number of Parkinson's cases globally within five years. The surge is linked to factors like increased industrialisation, air pollution, changing lifestyles, and a high rate of young-onset cases.


Q2: What is the primary challenge regarding Parkinson's treatment affordability in India?


The high cost of advanced treatments, sometimes reaching ₹1 lakh per month, poses a major barrier to care. Experts believe local manufacturing of novel therapies, such as a new treatment patch, could reduce this cost to as low as ₹1,000 per month.


Q3: What percentage of Parkinson's cases in India are considered early-onset?


Approximately 40-45% of Indian cases are classified as early-onset, occurring in individuals between the ages of 22 and 49.



Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.



References



  1. India expected to see surge in Parkinson's disease, becoming 2nd-highest in 5yrs: Experts - ETHealthworld

  2. Surging Parkinson's disease in India worries global experts as youth cases rise across Southeast Asia - Prameya News

  3. India Likely to Have Highest Absolute Prevalence of Parkinson's Disease in the World, Says Experts - Amrita Hospital

  4. The Evolving Global Burden of Young-Onset Parkinson's Disease (1990-2021): Regional, Gender, and Age Disparities in the Context of Rising Incidence and Declining Mortality - PubMed

Login to continue

More from MedShots Daily

India's Parkinson's Surge: Why Young-Onset Cases are Rising
India's Parkinson's Surge: Why Young-Onset Cases are Rising

Experts warn that India will soon have the world's 2nd-highest number of Parkinson's disease cases, with a significant rise in young-onset PD linked to envi...

last month

Read More
Full Text
Occupational Asthma: Why 36% of Workers Face Job Loss and Disability
Occupational Asthma: Why 36% of Workers Face Job Loss and Disability

A meta-analysis finds that 35.9% of occupational asthma patients face adverse outcomes like unemployment, highlighting the need for early workplace interven...

Today

Read More
Full Text
Social Determinants of Health, Diabetes, and Pregnancy: Understanding the Links
Social Determinants of Health, Diabetes, and Pregnancy: Understanding the Links

A look at how social determinants of health (SDOH) influence glycemic control and pregnancy outcomes for women living with diabetes....

Today

Read More
Full Text
Advancing Pulmonary Hypertension Therapy: Inhaled Riociguat Pharmacokinetics
Advancing Pulmonary Hypertension Therapy: Inhaled Riociguat Pharmacokinetics

A mouse study comparing solution and suspension dosing suggests inhaled riociguat provides sustained lung exposure, potentially improving PH management....

Today

Read More
Full Text
Zoledronate Outperforms Denosumab in Initial Protection Against Vertebral Fractures
Zoledronate Outperforms Denosumab in Initial Protection Against Vertebral Fractures

A cohort study reveals that zoledronate provides better initial protection against vertebral fractures than denosumab in treatment-naive osteoporosis patien...

Today

Read More
Full Text
Kallistatin's Role in Myosteatosis and Exercise Intolerance Revealed
Kallistatin's Role in Myosteatosis and Exercise Intolerance Revealed

New study finds elevated Kallistatin drives muscle fat accumulation and exercise intolerance by antagonizing AdipoR1-mediated AMPK signalling....

Today

Read More
Full Text
Showing Page 1 of 1(5 items total)
Go to Page

"Wherever the art of Medicine is loved, there is also a love of Humanity."

— Hippocrates

made with❤️byOmnicuris